Mira Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: MIRA · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5 million, $30.5 million, $30 million, $60 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
TL;DR
Mira Pharma's 8-K: Leadership shakeup, new officers elected, and votes coming up. Big changes afoot.
AI Summary
Mira Pharmaceuticals, Inc. filed an 8-K on September 11, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of new directors, the appointment of certain officers, and updates on compensatory arrangements for its officers. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This 8-K filing signals potential shifts in the leadership and governance of Mira Pharmaceuticals, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with votes by security holders, can indicate internal restructuring or strategic shifts that may carry inherent business risks.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- September 11, 2025 (date) — Date of Report
FAQ
Who are the specific directors or officers departing from Mira Pharmaceuticals, Inc.?
The filing indicates the departure of directors or certain officers but does not name the specific individuals in the provided text.
Were any new directors or officers elected or appointed as part of this 8-K filing?
Yes, the filing explicitly states the election of directors and the appointment of certain officers.
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
Are there any details regarding the compensatory arrangements of certain officers mentioned in the filing?
Yes, the filing notes that it covers compensatory arrangements of certain officers, but the specifics of these arrangements are not detailed in the provided text.
What is the primary business of Mira Pharmaceuticals, Inc. according to the filing?
According to the filing, Mira Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, with a Standard Industrial Classification code of 2834.
Filing Stats: 1,123 words · 4 min read · ~4 pages · Grade level 11.2 · Accepted 2025-09-11 17:25:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
- $5 million — mpany. At closing, SKNY will contribute $5 million in cash or assets to MIRA. Independent
- $30.5 million — gned enterprise values of approximately $30.5 million for SKNY (based on a risk-adjusted net
- $30 million — justed net present value of SKNY-1) and $30 million for MIRA, supporting a combined enterpr
- $60 million — combined enterprise value of more than $60 million for the merged entity. The Company expe
Filing Documents
- form8-k.htm (8-K) — 59KB
- 0001493152-25-013100.txt ( ) — 226KB
- mira-20250911.xsd (EX-101.SCH) — 3KB
- mira-20250911_lab.xml (EX-101.LAB) — 33KB
- mira-20250911_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: September 11, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer